40,931 CVS Health Corporation $CVS Shares Sold by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH reduced its position in shares of CVS Health Corporation (NYSE:CVS) by 5.7% in the third quarter, HoldingsChannel.com reports. The firm owned 681,086 shares of the pharmacy operator’s stock after selling 40,931 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in CVS Health were worth $58,362,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of CVS Health during the second quarter valued at approximately $12,747,462,000. State Street Corp lifted its stake in CVS Health by 26.3% in the second quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock worth $7,751,205,000 after acquiring an additional 15,604,883 shares during the period. Bank of America Corp DE lifted its stake in CVS Health by 148.0% in the second quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock worth $2,398,868,000 after acquiring an additional 13,836,701 shares during the period. Pzena Investment Management LLC bought a new stake in CVS Health in the second quarter valued at $1,217,558,000. Finally, Wellington Management Group LLP boosted its holdings in CVS Health by 49.8% in the second quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock valued at $3,496,725,000 after acquiring an additional 11,233,381 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

CVS Health Stock Performance

Shares of CVS stock opened at $90.42 on Thursday. The company has a market capitalization of $115.64 billion, a price-to-earnings ratio of 23.92, a price-to-earnings-growth ratio of 0.82 and a beta of 0.60. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The company’s 50-day moving average is $91.88 and its 200 day moving average is $92.87. CVS Health Corporation has a one year low of $69.51 and a one year high of $110.68.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts expect that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be paid a $0.6650 dividend. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. CVS Health’s payout ratio is currently 70.37%.

Analysts Set New Price Targets

A number of brokerages have issued reports on CVS. Leerink Partners reduced their price objective on shares of CVS Health from $119.00 to $112.00 and set an “outperform” rating on the stock in a research report on Monday. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CVS Health in a research note on Friday, October 9th. Robert W. Baird set a $107.00 price target on shares of CVS Health in a research report on Thursday, August 6th. Royal Bank Of Canada raised their price objective on shares of CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. Finally, Argus lifted their price objective on CVS Health from $104.00 to $114.00 and gave the company a “buy” rating in a research report on Wednesday, August 19th. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Aetna reported that more than 69% of its Medicare Advantage members are enrolled in plans rated four stars or higher for 2027, marking the third consecutive year of strong performance among large publicly traded insurers. Higher star ratings can support member retention and Medicare Advantage revenue. Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
• Positive Sentiment: MinuteClinic received its seventh consecutive Joint Commission accreditation, with approximately 80% of surveyed locations offering primary care. The recognition supports CVS’s strategy to expand accessible, lower-cost healthcare services. MinuteClinic accreditation
• Positive Sentiment: CVS opened its first pharmacy-focused location in the Boston area, aimed at improving access to medications, vaccinations and other pharmacy services in underserved communities. CVS Pharmacy opens Boston-area location
• Neutral Sentiment: One analyst comparison said CVS currently benefits from stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare, with Aetna’s turnaround supporting the investment case. This is analyst sentiment rather than a new company financial result. CVS versus Alignment Healthcare
• Negative Sentiment: CVS Pharmacy and related entities agreed to pay $315 million to resolve a U.S. Justice Department case alleging that pharmacies filled unlawful or medically unnecessary opioid and other controlled-substance prescriptions from 2013 through 2025 and submitted false claims to federal healthcare programs. CVS admitted no wrongdoing and strongly disputes the allegations, but the settlement creates a direct cost, reputational damage and additional compliance obligations, including tighter prescription monitoring. The development is the main reason the stock is likely under pressure, while also renewing scrutiny of former and current company leadership. Justice Department CVS opioid settlement

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.